A federal docket on the therapeutic use of psychedelics is open through October 5. Four groups that built this movement from the ground up on what they’d ...

This week’s newsletter covers psychedelic turf wars erupting in Toronto’s grey market, ketamine therapy concerns among law enforcement, ayahuasca’s ...

This week’s newsletter covers the uncertain fate of cannabis rescheduling under the Trump administration, along with new research on psychedelic ...

This week’s newsletter covers the latest research and journalism on plant medicine, including a landmark study on psilocybin microdosing and ...

This week’s newsletter covers MDMA’s potential effects on memory, safety concerns around ibogaine, ethical questions in the psychedelic investment ...

This week’s newsletter explores the political roots of psychedelic prohibition, ancient uses of mind-altering substances, new research on how ...

This week’s newsletter covers whole-plant cannabis extracts versus isolated THC for chronic pain, the intersection of mental health and cannabis use, ...

This week’s newsletter covers a federally funded study on cannabis access and opioid overdose reduction, the potential of CBD-derived plastics, the ...

This week’s newsletter covers an Iranian study on CBD bioavailability and delivery methods, critiques of Canada’s cannabis market and flavored vape ...

This week’s newsletter covers a promising psychedelic therapy pilot study for clinical depression, psilocybin research on dementia and childhood ...